nach oben

Endocrine

Erschienen in:

01.04.2015 | Review

Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment

verfasst von: Federica Barutta, Graziella Bruno, Serena Grimaldi, Gabriella Gruden

Erschienen in: Endocrine | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Diabetic nephropathy (DN) is a leading cause of end stage renal failure and there is an urgent need to identify new clinical biomarkers and targets for treatment to effectively prevent and slow the progression of the complication. Many lines of evidence show that inflammation is a cardinal pathogenetic mechanism in DN. Studies in animal models of experimental diabetes have demonstrated that there is a low-grade inflammation in the diabetic kidney. Both pharmacological and genetic strategies targeting inflammatory molecules have been shown to be beneficial in experimental DN. In vitro studies have cast light on the cellular mechanisms whereby diabetes triggers inflammation and in turn inflammation magnifies the kidney injury. Translation of this basic science knowledge into potential practical clinical applications is matter of great interest for researchers today. This review focuses on key pro-inflammatory systems implicated in the development of DN: the tumor necrosis factor(TNF)-α/TNF-α receptor system, the monocyte chemoattractant protein-1/CC-chemokine receptor-2 system, and the Endocannabinoid system that have been selected as they appear particularly promising for future clinical applications.

American Diabetes Association, Standards of medical care in diabetes. Diabetes Care 37(suppl.1), S42–S44 (2014)

L.A. Stevens, T. Greene, A.S. Levey, Surrogate end points for clinical trials of kidney disease progression. Clin. J. Am. Soc. Nephrol. 1, 874–884 (2006)PubMed

H.J. Lambers Heerspink, D. de Zeeuw, Debate: PRO position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am. J. Nephrol. 31, 458–461 (2010)PubMed

R.J. Glassock, Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am. J. Nephrol. 31, 462–465 (2010)PubMed

R.J. Macisaac, G. Jerums, Diabetic kidney disease with and without albuminuria. Curr. Opin. Nephrol. Hypertens. 20, 246–257 (2011)PubMed

G. Penno, A. Solini, E. Bonora, C. Fondelli, E. Orsi, G. Zerbini, R. Trevisan, M. Vedovato, G. Gruden, F. Cavalot, M. Cignarelli, L. Laviola, S. Morano, A. Nicolucci, G. Pugliese, Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J. Hypertens. 29, 1802–1809 (2011)PubMed

DCCT. The effect of intensive treatment of diabetes on the development and progression of long term complications in the insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977–86 (1993)

UK Prospective Diabetes Study, UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33. Lancet 12, 837–853 (1998)

E.J. Lewis, L.G. Hunsicker, R.P. Bain, R.D. Rohde, The effect of ACE inhibition on diabetic nephropathy. N. Engl. J. Med. 329, 1456–1462 (1993)PubMed

10.

A.S. Krolewski, M. Canessa, J.H. Warram, L.M. Laffel, A.R. Christlieb, W.C. Knowler, L.I. Rand, Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N. Engl. J. Med. 318, 140 (1988)PubMed

11.

P. Gaede, P. Vedel, H.H. Parving, O. Pedersen, Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 20(353), 617–622 (1999)

12.

T. Furuta, T. Saito, T. Ootaka, J. Soma, K. Obara, K. Abe, K. Yoshinaga, The role of macrophages in diabetic glomerulosclerosis. Am. J. Kidney Dis. 21, 480–485 (1993)PubMed

13.

C. Viedt, S.R. Orth, Monocyte chemoattractant protein-1 (MCP-1) in the kidney: does it more than simply attract monocytes? Nephrol. Dial. Transplant. 17, 2043–2047 (2002)PubMed

14.

C. Sassy-Prigent, D. Heudes, C. Mandet, M.F. Bélair, O. Michel, B. Perdereau, J. Bariéty, P. Bruneval, Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 49, 466–475 (2000)PubMed

15.

H. Sugimoto, K. Shikata, K. Hirata, K. Akiyama, M. Matsuda, M. Kushiro, Y. Shikata, N. Miyatake, M. Miyasaka, H. Makino, Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation. Diabetes 46, 2075–2081 (1997)PubMed

16.

S. Kato, V.A. Luyckx, M. Ots, K.W. Lee, F. Ziai, J.L. Troy, B.M. Brenner, H.S. MacKenzie, Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int. 56, 1037–1048 (1999)PubMed

17.

S. Okada, K. Shikata, M. Matsuda, D. Ogawa, H. Usui, Y. Kido, R. Nagase, J. Wada, Y. Shikata, H. Makino, Intercellular adhesion molecule-1—deficient mice are resistant against renal injury after induction of diabetes. Diabetes 52, 2586–2593 (2003)PubMed

18.

F.Y. Chow, D.J. Nikolic-Paterson, E. Ozols, R.C. Atkins, B.J. Rollin, G.H. Tesch, Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 69, 73–80 (2006)PubMed

19.

H. You, T. Gao, T.K. Cooper, W. Brian Reeves, A.S. Awad, Macrophages directly mediate diabetic renal injury. Am. J. Physiol. Renal Physiol. 305, F1719–F1727 (2013)PubMedPubMedCentral

20.

I.Z. Pawluczyk, K.P. Harris, Macrophages promote prosclerotic responses in cultured rat mesangial cells: a mechanism for the initiation of glomerulosclerosis. J. Am. Soc. Nephrol. 8, 1525–1536 (1997)PubMed

21.

Y. Ikezumi, T. Suzuki, T. Karasawa, H. Kawachi, D.J. Nikolic-Paterson, M. Uchiyama, Activated macrophages down-regulate podocyte nephrin and podocin expression via stress-activated protein kinases. Biochem. Biophys. Res. Commun. 376, 706–711 (2008)PubMed

22.

C.W. Park, J.H. Kim, J.H. Lee, Y.S. Kim, H.J. Ahn, Y.S. Shin, S.Y. Kim, E.J. Choi, Y.S. Chang, B.K. Bang, High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-kappa B-dependent. Diabetologia 43, 1544–1553 (2000)PubMed

23.

F. Chow, E. Ozols, D.J. Nikolic-Paterson, R.C. Atkins, G.H. Tesch, Macrophage in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 65, 116–128 (2004)PubMed

24.

F.Y. Chow, D.J. Nikolic-Paterson, F.Y. Ma, E. Ozols, B.J. Rollins, G.H. Tesch, Monocyte chemoattractant protein 1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia 50, 471–480 (2007)PubMed

25.

S.D. Ricardo, H. van Goor, A.A. Eddy, Macrophage diversity in renal injury and repair. J. Clin. Invest. 118, 3522–3530 (2008)PubMedPubMedCentral

26.

D. Zheng, Y. Wang, Q. Cao, V.W. Lee, G. Zheng, Y. Sun, T.K. Tan, Y. Wang, S.I. Alexander, D.C. Harris, Transfused macrophages ameliorate pancreatic and renal injury in murine diabetes mellitus. Nephron Exp. Nephrol. 118, e87–e99 (2011)PubMed

27.

P.J. Naudé, J.A. den Boer, P.G. Luiten, U.L. Eisel, Tumor necrosis factor receptor cross-talk. FEBS J. 278, 888–898 (2011)PubMed

28.

A. Ortiz, C. Bustos, J. Alonso, R. Alcázar, M.J. López-Armada, J.J. Plaza, E. González, J. Egido, Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental, and human glomerulonephritis. Adv. Nephrol. Necker Hosp. 24, 53–77 (1995)PubMed

29.

S.M. Laster, J.G. Wood, L.R. Gooding, Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J. Immunol. 141, 2629–2634 (1988)PubMed

30.

J.J. Boyle, P.L. Weissberg, M.R. Bennett, Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. Arterioscler. Thromb. Vasc. Biol. 23, 1553–1558 (2003)PubMed

31.

J.A. McKenzie, A.J. Ridley, Roles of Rho/ROCK and MLCK in TNF-alpha-induced changes in endothelial morphology and permeability. J. Cell Physiol. 213, 221–228 (2007)PubMed

32.

H.H. Radeke, B. Meier, N. Topley, J. Flöge, G.G. Habermehl, K. Resch, Interleukin 1-alpha and tumor necrosis factor-alpha induce oxygen radical production mesangial cells. Kidney Int. 37, 767–775 (1990)PubMed

33.

G. Hasegawa, K. Nakano, M. Sawada, K. Uno, Y. Shibayama, K. Ienaga, M. Kondo, Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int. 40, 1007–1012 (1991)PubMed

34.

L. Baud, J.P. Oudinet, M. Bens, L. Noe, M.N. Peraldi, E. Rondeau, J. Etienne, R. Ardaillou, Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. Kidney Int. 35, 1111–1118 (1989)PubMed

35.

A.K. Hughes, P.K. Stricklett, D.E. Kohan, Shiga toxin-1 regulation of cytokine production by human glomerular epithelial cells. Nephron. 88, 14–23 (2001)PubMed

36.

A.M. Jevnikar, D.C. Brennan, G.G. Singer, J.E. Heng, W. Maslinski, R.P. Wuthrich, L.H. Glimcher, V.E. Kelley, Stimulated kidney tubular epithelial cells express membrane associated and secreted TNF-α. Kidney Int. 40, 203–211 (1991)PubMed

37.

X.H. Wu, S.M. Huang, W.X. Fan, W.X. Tang, H.Y. Qiu, Influence of high glucose and mannose binding lectin complement pathway activation to IL-6 and TNF-alpha’s expression by human renal glomerular endothelial cells. Sichuan Da Xue Xue Bao Yi Xue Ban. 42, 90–94. Chinese. (2011)

38.

H. Sugimoto, K. Shikata, J. Wada, S. Horiuchi, H. Makino, Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia 42, 878–886 (1999)PubMed

39.

K. Omote, T. Gohda, M. Murakoshi, Y. Sasaki, S. Kazuno, T. Fujimura, M. Ishizaka, Y. Sonoda, Y. Tomino, Role of the TNF pathway in the progression of diabetic nephropathy in KK-A^y mice. Am. J. Physiol. Renal Physiol. 306, F1335–F1347 (2014)PubMed

40.

K. Kalantarinia, A.S. Awad, H.M. Siragy, Urinary and renal interstitial concentrations of TNF-α increase prior to the rise in albuminuria in diabetic rats. Kidney Int. 64, 1208–1213 (2003)PubMed

41.

Y. Moriwaki, T. Inokuchi, A. Yamamoto, T. Ka, Z. Tsutsumi, S. Takahashi, T. Yamamoto, Effect of TNF-α inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol. 44, 215–218 (2007)PubMed

42.

R. Pai, B. Bassa, M.A. Kirschenbaum, V.S. Kamanna, TNF-alpha stimulates monocyte adhesion to glomerular mesangial cells. The role of intercellular adhesion molecule-1 gene expression and protein kinases. J. Immunol. 156, 2571–2579 (1996)PubMed

43.

S.K. Lee, J.Y. Park, S.J. Chung, W.S. Yang, S.B. Kim, S.K. Park, J.S. Park, Chemokines, osteopontin, ICAM-1 gene expression in cultured rat mesangial cells. J. Korean Med. Sci. 13, 165–170 (1998)PubMedPubMedCentral

44.

A. Marfaing-Koka, O. Devergne, G. Gorgone, A. Portier, T.J. Schall, P. Galanaud, D. Emilie, Regulation of the production of the RANTES chemokine by endothelial cells. Synergistic induction by IFN-gamma plus TNF-alpha and inhibition by IL-4 and IL-13. J. Immunol. 154, 1870–1878 (1995)PubMed

45.

V.S. Kamanna, R. Pai, B. Bassa, M.A. Kirschenbaum, Activation of mesangial cells with TNF-alpha stimulates M-CSF gene expression and monocyte proliferation: evidence for involvement of protein kinase C and protein tyrosine kinase. Biochim. Biophys. Acta 1313, 161–172 (1996)PubMed

46.

G. Wolf, S. Aberle, F. Thaiss, P.J. Nelson, A.M. Krensky, E.G. Neilson, R.A. Stahl, TNF alpha induces expression of the chemoattractant cytokine RANTES in cultured mouse mesangial cells. Kidney Int. 44, 795–804 (1993)PubMed

47.

C. Zoja, J.M. Wang, S. Bettoni, M. Sironi, D. Renzi, F. Chiaffarino, H.E. Abboud, J. Van Damme, A. Mantovani, G. Remuzzi, Interleukin-1 beta and tumor necrosis factor-alpha induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells. Am. J. Pathol. 138, 991–1003 (1991)PubMedPubMedCentral

48.

A. Taubitz, M. Schwarz, N. Eltrich, M.T. Lindenmeyer, V. Vielhaue, Distinct contributions of TNF receptor 1 and 2 to TNF-induced glomerular inflammation in mice. PLoS One 8, e68167 (2013)PubMedPubMedCentral

49.

Z. Hruby, K.F. Beck, Cytotoxic effect of autocrine and macrophage derived nitric oxide on cultured rat mesangial cells. Clin. Exp. Immunol. 107, 76–82 (1997)PubMedPubMedCentral

50.

I.Z. Pawluczyk, K.P. Harris, Cytokine interactions promote synergistic fibronectin accumulation by mesangial cells. Kidney Int. 54, 62–70 (1998)PubMed

51.

N. Koike, T. Takamura, S. Kaneko, Induction of reactive oxygen species from isolated rat glomeruli by protein kinase C activation and TNF- stimulation, and effects of a phosphodiesterase inhibitor. Life Sci. 80, 1721–1728 (2007)PubMed

52.

K. Yamauchi, Y. Takano, A. Kasai, K. Hayakawa, N. Hiramatsu, N. Enomoto, J. Yao, M. Kitamura, Screening and identification of substances that regulate nephrin gene expression using engineered reporter podocytes. Kidney Int. 70, 892–900 (2006)PubMed

53.

Y. Takano, K. Yamauchi, K. Hayakawa, N. Hiramatsu, A. Kasai, M. Okamura, M. Yokouchi, A. Shitamura, J. Yao, M. Kitamura, Transcriptional suppression of nephrin in podocytes by macrophages: role of inflammatory cytokines and involvement of the PI3K/Akt pathway. FEBS Lett. 581, 421–426 (2007)PubMed

54.

S. Doublier, V. Ruotsalainen, G. Salvidio, E. Lupia, L. Biancone, P.G. Conaldi, P. Reponen, K. Tryggvason, G. Camussi, Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. Am. J. Pathol. 158, 1723–1731 (2001)PubMedPubMedCentral

55.

S.B. Koukouritaki, E.A. Vardaki, E.A. Papakonstanti, E. Lianos, C. Stournaras, D.S. Emmanouel, TNF-alpha induces actin cytoskeleton reorganization in glomerular epithelial cells involving tyrosine phosphorylation of paxillin and focal adhesion kinase. Mol. Med. 5, 382–392 (1999)PubMedPubMedCentral

56.

T. Tejada, P. Catanuto, A. Ijaz, J.V. Santos, X. Xia, P. Sanchez, N. Sanabria, O. Lenz, S.J. Elliot, A. Fornoni, Failure to phosphorylate AKT in podocytes from mice with early diabetic nephropathy promotes cell death. Kidney Int. 73, 1385–1393 (2008)PubMed

57.

J. Han, P. Thompson, B. Beutler, Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signalling pathway. J. Exp. Med. 172, 393–394 (1990)

58.

G.M. Doherty, J.C. Jensen, H.R. Alexander, C.M. Buresh, J.A. Norton, Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery. 110, 192–198 (1991)PubMed

59.

M.C. Thomas, Emerging drugs for managing kidney disease in patients with diabetes. Expert Opin. Emerging Drugs. 18, 55–70 (2013)

60.

B.B. McCormick, A. Sydor, A. Akbari, D. Fergusson, S. Doucette, G. Knoll, The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am. J. Kidney Dis. 52, 454–463 (2008)PubMed

61.

J.F. Navarro-González, C. Mora-Fernández, M. Muros de Fuentes, M.L. Méndez, E. Gallego, M. Macía, N. Del Castillo, A. Rivero, N. Del Castillo, M.A. Getino, P. García, A. Jarque, J. García, Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J. Am. Soc. Nephrol. (2014). doi:10.1681/ASN.2014010012 PubMed

62.

M.H. Bemelmans, L.J. van Tits, W.A. Buurman, Tumor necrosis factor: function, release and clearance. Crit. Rev. Immunol. 16, 1–11 (1996)

63.

Y. Moriwaki, T. Yamamoto, Y. Shibutani, E. Aoki, Z. Tsutsumi, S. Takahashi, H. Okamura, M. Koga, M. Fukuchi, T. Hada, Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism. 53, 605–608 (2003)

64.

J.F. Navarro, C. Mora, M. Muros, J. García, Urinary tumour necrosis factor-α excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol. Dial. Transplant. 21(12), 3428–3434 (2006)PubMed

65.

G. Gruden, F. Barutta, N. Chaturvedi, C. Schalkwijk, C.D. Stehouwer, S. Pinach, M. Manzo, M. Loiacono, M. Tricarico, G. Mengozzi, D.R. Witte, J.H. Fuller, P.C. Perin, G. Bruno, NH2-terminal probrain natriuretic peptide is associated with diabetes complications in the EURODIAB Prospective Complications Study: the role of tumor necrosis factor-α. Diabetes Care 35, 1931–1936 (2012)PubMedPubMedCentral

66.

J. Lin, F.B. Hu, E.B. Rimm, N. Rifai, G.C. Curhan, The association of serum lipids and inflammatory biomarkers with renal function in men with type II diabetes mellitus. Kidney Int. 69, 336–342 (2006)PubMedPubMedCentral

67.

M.A. Niewczas, L.H. Ficociello, A.C. Johnson, W. Walker, E.T. Rosolowsky, B. Roshan, J.H. Warram, A.S. Krolewski, Serum concentrations of markers of TNFα and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin. J. Am. Soc. Nephrol. 4, 62–70 (2009)PubMedPubMedCentral

68.

T. Gohda, M.A. Niewczas, L.H. Ficociello, W.H. Walker, J. Skupien, F. Rosetti, X. Cullere, A.C. Johnson, G. Crabtree, A.M. Smiles, T.N. Mayadas, J.H. Warram, A.S. Krolewski, Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J. Am. Soc. Nephrol. 23, 516–524 (2012)PubMedPubMedCentral

69.

M.A. Niewczas, T. Gohda, J. Skupien, A.M. Smiles, W.H. Walker, F. Rosetti, X. Cullere, J.H. Eckfeldt, A. Doria, T.N. Mayadas, J.H. Warram, A.S. Krolewski, Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J. Am. Soc. Nephrol. 23, 507–515 (2012)PubMedPubMedCentral

70.

M.F. Lopes-Virella, N.L. Baker, K.J. Hunt, P.A. Cleary, R. Klein, G. Virella, DCCT/EDIC Research Group.: Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care 36, 2317–2323 (2013)PubMedPubMedCentral

71.

C. Forsblom, J. Moran, V. Harjutsalo, T. Loughman, J. Wadén, N. Tolonen, L. Thorn, M. Saraheimo, D. Gordin, P.H. Groop, M.C. Thomas, on behalf of the FinnDiane Study Group, Added value of soluble Tumor Necrosis Factor Alpha Receptor-1 as a biomarker of ESRD risk. Diabetes Care (2014). doi:10.2337/dc14-0225

72.

J. Lin, F.B. Hu, C. Mantzoros, G.C. Curhan, Lipid and inflammatory biomarkers and kidney function decline in type 2 diabetes. Diabetologia 53, 263–267 (2010)PubMedPubMedCentral

73.

F.T. Lee, Z. Cao, D.M. Long, S. Panagiotopoulos, G. Jerums, M.E. Cooper, J.M. Forbes, Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J. Am. Soc. Nephrol. 15, 2139–2151 (2004)PubMed

74.

S. Mezzano, A. Droguett, M.E. Burgos, L.G. Ardiles, C.A. Flores, C.A. Aros, I. Caorsi, C.P. Vío, M. Ruiz-Ortega, J. Egido, Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int. Suppl. 86, S64–S70 (2003)PubMed

75.

E. Tarabra, S. Giunti, F. Barutta, G. Salvidio, D. Burt, G. Deferrari, R. Gambino, D. Vergola, S. Pinach, P.C. Perin, G. Camussi, G. Gruden, Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes 58, 2109–2118 (2009)PubMedPubMedCentral

76.

N. Banba, T. Nakamura, M. Matsumura, H. Kuroda, Y. Hattori, K. Kasai, Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int. 58, 684–690 (2000)PubMed

77.

H. Ha, M.R. Yu, Y.J. Choi, M. Kitamura, H.B. Lee, Role of high glucose–induced nuclear factor-B activation in monocyte chemoattractant protein-1 expression by mesangial cells. J. Am. Soc. Nephrol. 13, 894–902 (2002)PubMed

78.

M. Naito, A. Shenoy, I. Aoyama, J.S. Koopmeiners, R. Komers, H.W. Schnaper, K. Bomsztyk, High ambient glucose augments angiotensin ii-induced proinflammatory gene mrNA expression in human mesangial cells: effects of valsartan and simvastatin. Am. J. Nephrol. 30, 99–111 (2009)PubMedPubMedCentral

79.

C.G. Ihm, J.K. Park, S.P. Hong, T.W. Lee, B.S. Cho, M.J. Kim, D.R. Cha, H. Ha, A high glucose concentration stimulates the expression of monocyte chemotactic peptide 1 in human mesangial cells. Nephron. 79, 33–37 (1998)PubMed

80.

S.Y. Han, G.A. So, Y.H. Jee, K.H. Han, Y.S. Kang, H.K. Kim, S.W. Kang, D.S. Han, J.Y. Han, D.R. Cha, Effect of retinoic acid in experimental diabetic nephropathy. Immunol. Cell Biol. 82, 568–576 (2004)PubMed

81.

E.Y. Lee, C.H. Chung, C.C. Khoury, T.K. Yeo, P.E. Pyagay, A. Wang, S. Chen, The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability. Am. J. Physiol. Renal Physiol. 297, F85–F94 (2009)PubMedPubMedCentral

82.

T. Matsui, S. Yamagishi, M. Takeuchi, S. Ueda, K. Fukami, S. Okuda, Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferatoractivated receptor-gamma activation. Biochem. Biophys. Res. Commun. 385, 269–272 (2009)PubMed

83.

T. Matsui, S. Yamagishi, S. Ueda, K. Nakamura, T. Imaizumi, M. Takeuchi, H. Inoue, Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. J. Int. Med. Res. 35, 482–489 (2007)PubMed

84.

L. Gu, S. Hagiwara, Q. Fan, M. Tanimoto, M. Kobata, M. Yamashita, T. Nishitani, T. Gohda, Z. Ni, J. Qian, S. Horikoshi, Y. Tomino, Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol. Dial. Transplant. 21, 299–313 (2006)PubMed

85.

G. Gruden, G. Setti, A. Hayward, D. Sugden, S. Duggan, D. Burt, R.E. Buckingham, L. Gnudi, G. Viberti, Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone. J. Am. Soc. Nephrol. 16, 688–696 (2005)PubMed

86.

J. Cheng, M.M. Diaz Encarnacion, G.M. Warner, C.E. Gray, K.A. Nath, J.P. Grande, TGF-beta1 stimulates monocyte chemoattractant protein-1 expression in mesangial cells through a phosphodiesterase isoenzyme 4-dependent process. Am. J. Physiol. Cell Physiol. 289, C959–C970 (2005)PubMed

87.

W. Qi, X. Chen, T.S. Polhill, S. Sumual, S. Twigg, R.E. Gilbert, C.A. Pollock, TGF-β1 induces IL-8 and MCP-1 through a connective tissue growth factor-independent pathway. Am. J. Physiol. Renal Physiol. 290, F703–F709 (2006)PubMed

88.

B.H. Rovin, T. Yoshiumura, L. Tan, Cytokine-induced production of monocyte chemoattractant protein-1 by cultured human mesangial cells. J. Immunol. 148, 2148–2153 (1992)PubMed

89.

Y. Watanabe, M. Tamura, A. Osajima, H. Anai, N. Kabashima, R. Serino, Y. Nakashima, Integrins induce expression of monocyte chemoattractant protein-1 via focal adhesion kinase in mesangial cells. Kidney Int. 64, 431–440 (2003)PubMed

90.

A.A. Eddy, C.M. Giachelli, Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int. 47, 1546–1557 (1995)PubMed

91.

Y. Wang, J. Chen, L. Chen, Y.C. Tay, G.K. Rangan, D.C. Harris, Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J. Am. Soc. Nephrol. 8, 1537–1545 (1997)PubMed

92.

S. Giunti, Targeting the MCP-1/CCR2 system in diabetic kidney disease. Curr. Vasc. Pharmacol. 8, 849–860 (2010)PubMed

93.

S. Giunti, F. Barutta, P.C. Perin, G. Gruden, The MCP-1/CCR2 system has direct proinflammatory effects in human mesangial cells. Kidney Int. 69, 856–863 (2006)PubMed

94.

D. Burt, G. Salvidio, E. Tarabra, F. Barutta, S. Pinach, P. Dentelli, G. Camussi, P.C. Perin, G. Gruden, The monocyte chemoattractant protein-1/cognate CC chemokine receptor 2 system affects cell motility in cultured human podocytes. Am. J. Pathol. 171, 1789–1799 (2007)PubMedPubMedCentral

95.

V.H. Rao, D.T. Meehan, D. Delimont, M. Nakajima, T. Wada, M.A. Gratton, D. Cosgrove, Role for macrophage metalloelastase in glomerular basement membrane damage associated with alport syndrome. Am. J. Pathol. 169, 32–46 (2006)PubMedPubMedCentral

96.

S. Giunti, G.H. Tesch, S. Pinach, D.J. Burt, M.E. Cooper, P. Cavallo-Perin, G. Camussi, G. Gruden, Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia 51, 198–207 (2008)PubMed

97.

J. Park, D.R. Ryu, J.J. Li, D.S. Jung, S.J. Kwak, S.H. Lee, T.H. Yoo, S.H. Han, J.E. Lee, D.K. Kim, S.J. Moon, K. Kim, D.S. Han, S.W. Kang, MCP-1/CCR2 system is involved in high glucose-induced fibronectin and type IV collagen expression in cultured mesangial cells. Am. J. Physiol. Renal Physiol. 295, F749–F757 (2008)PubMed

98.

B.Y. Nam, J. Paeng, S.H. Kim, S.H. Lee, H. do Kim, H.Y. Kang, J.J. Li, S.J. Kwak, J.T. Park, T.H. Yoo, S.H. Han, D.K. Kim, S.W. Kang, The MCP-1/CCR2 axis in podocytes is involved in apoptosis induced by diabetic conditions. Apoptosis 17, 1–13 (2012)PubMed

99.

H. Kanamori, T. Matsubara, A. Mima, E. Sumi, K. Nagai, T. Takahashi, H. Abe, N. Iehara, A. Fukatsu, H. Okamoto, T. Kita, T. Doi, H. Arai, Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem. Biophys. Res. Commun. 360, 772–777 (2007)PubMed

100.

P. Celec, J. Hodosy, R. Gardlík, M. Behuliak, R. Pálffy, M. Pribula, P. Jáni, J. Turňa, K. Sebeková, The effects of anti-Inflammatory and anti-angiogenic DNA vaccination on diabetic nephropathy in rats. Hum. Gene Ther. 23, 158–166 (2012)PubMedPubMedCentral

101.

A.S. Awad, G.R. Kinsey, K. Khutsishvili, T. Gao, W.K. Bolton, M.D. Okusa, Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury. Am. J. Physiol. Renal Physiol. 301, F1358–F1366 (2011)PubMedPubMedCentral

102.

S.J. Seok, E.S. Lee, G.T. Kim, M. Hyun, J.H. Lee, S. Chen, R. Choi, H.M. Kim, E.Y. Lee, C.H. Chung, Blockade of CCL2/CCR2 signalling ameliorates diabetic nephropathy in db/db mice. Nephrol. Dial. Transplant. 28, 1700–1710 (2013)PubMed

103.

M. Okamoto, M. Fuchigami, T. Suzuki, N. Watanabe, A novel C-C chemokine receptor 2 antagonist prevents progression of albuminuria and atherosclerosis in mouse models. Biol. Pharm. Bull. 35, 2069–2074 (2012)PubMed

104.

S.G. Sayyed, M. Ryu, O.P. Kulkarni, H. Schmid, J. Lichtnekert, S. Grüner, L. Green, P. Mattei, G. Hartmann, H.J. Anders, An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. Kidney Int. 80, 68–78 (2011)PubMed

105.

T.J. Sullivan, Z. Miao, D.J. Dairaghi, A. Krasinski, Y. Wang, B.N. Zhao, T. Baumgart, L.S. Ertl, A. Pennell, L. Seitz, J. Powers, R. Zhao, S. Ungashe, Z. Wei, L. Boring, C.L. Tsou, I. Charo, R.D. Berahovich, T.J. Schall, J.C. Jaen, CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice. Am. J. Physiol. Renal Physiol. 305, F1288–F1297 (2013)PubMedPubMedCentral

106.

T.J. Sullivan, Z. Miao, B.N. Zhao, L.S. Ertl, Y. Wang, A. Krasinski, M.J. Walters, J.P. Powers, D.J. Dairaghi, T. Baumgart, L.C. Seitz, R.D. Berahovich, T.J. Schall, J.C. Jaen, Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes. Metab. Clin. Exp. 62, 1623–1632 (2013)PubMed

107.

J.F. Navarro-González, C. Mora-Fernández, M. de Muros Fuentes, J. García-Pérez, Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat. Rev. Nephrol. 7, 327–340 (2011)PubMed

108.

M. Hanefeld, E. Schell, I. Gouni-Berthold, M. Melichar, I. Vesela, D. Johnson, S. Miao, T.J. Sullivan, J.C. Jaen, T.J. Schall, P. Bekker, the CCX140-B Diabetes Study Group, Orally-administered chemokine receptor CCR2 antagonist CCX140-B in type 2 diabetes: a pilot double-blind, randomized clinical trial. J. Diabetes Metabolism. 3, 9 (2012)

109.

V. Ninichuk, S. Clauss, O. Kulkarni, H. Schmid, S. Segerer, E. Radomska, D. Eulberg, K. Buchner, N. Selve, S. Klussmann, H.J. Anders, Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3’PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice. Am. J. Pathol. 172, 628–637 (2008)PubMedPubMedCentral

110.

S. Kiyici, E. Erturk, F. Budak, C. Ersoy, E. Tuncel, C. Duran, B. Oral, D. Sigirci, S. Imamoglu, Serum monocyte chemoattractant protein-1 and monocyte adhesion molecules in type 1 diabetic patients with nephropathy. Arch. Med. Res. 37, 998–1003 (2006)PubMed

111.

T. Wada, K. Furuichi, N. Sakai, Y. Iwata, K. Yoshimoto, M. Shimizu, S.I. Takeda, K. Takasawa, M. Yoshimura, H. Kida, K.I. Kobayashi, N. Mukaida, T. Naito, K. Matsushima, H. Yokoyama, Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int. 58, 1492–1499 (2000)PubMed

112.

N.G. Frangogiannis, The prognostic value of monocyte chemoattractant protein-1/CCL2 in acute coronary syndromes. J. Am. Coll. Cardiol. 50, 2125–2127 (2007)PubMed

113.

T. Morii, H. Fujita, T. Narita, T. Shimotomai, H. Fujishima, N. Yoshioka, H. Imai, M. Kakei, S. Ito, Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J. Diabetes Complicat. 17(1), 11–15 (2003)PubMed

114.

F.W. Tam, B.L. Riser, K. Meeran, J. Rambow, C.D. Pusey, A.H. Frankel, Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy. Cytokine 47, 37–42 (2009)PubMed

115.

M. Kano, T. Ohno-Shosaku, Y. Hashimotodani, M. Uchigashima, M. Watanabe, Endocannabinoid-mediated control of synaptic transmission. Physiol. Rev. 9, 309–380 (2009)

116.

J. Tam, J. Liu, B. Mukhopadhyay, R. Cinar, G. Godlewski, G. Kunos, Endocannabinoids in liver disease. Hepatology 53, 346–355 (2011)PubMedPubMedCentral

117.

P. Pacher, P. Mukhopadhyay, R. Mohanraj, G. Godlewski, S. Bátkai, G. Kunos, Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. Hypertension 52, 601–607 (2008)PubMedPubMedCentral

118.

C. Silvestri, V. Di Marzo, The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab. 17, 475–490 (2013)PubMed

119.

N. Leleu-Chavain, M. Body-Malapel, J. Spencer, P. Chavatte, P. Desreumaux, R. Millet, Recent advances in the development of selective CB(2) agonists as promising anti-inflammatory agents. Curr. Med. Chem. 19, 3457–3474 (2012)PubMed

120.

F. Barutta, F. Piscitelli, S. Pinach, G. Bruno, R. Gambino, M.P. Rastaldi, G. Salvidio, V. Di Marzo, P. Cavallo Perin, G. Gruden, Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes 60, 2386–2396 (2011)PubMedPubMedCentral

121.

F. Barutta, A. Corbelli, R. Mastrocola, R. Gambino, V. Di Marzo, S. Pinach, M.P. Rastaldi, P.C. Perin, G. Gruden, Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes 59, 1046–1054 (2010)PubMedPubMedCentral

122.

K.H. Han, S. Lim, J. Ryu, C.W. Lee, Y. Kim, J.H. Kang, S.S. Kang, Y.K. Ahn, C.S. Park, J.J. Kim, CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc. Res. 84, 378–386 (2009)PubMed

123.

D.H. Nam, Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice. Endocrinology 153, 1387–1396 (2012)PubMed

124.

J.C. Lim, M.H. Lee, J.E. Kim, H.K. Song, Y.S. Kang, J.E. Lee, H.W. Kim, J.J. Cha, Y.Y. Hyun, S.H. Kim, S.Y. Han, K.H. Han, J.Y. Han, D.R. Cha, Cannabinoid receptor 1 mediates high glucose-induced apoptosis via endoplasmic reticulum stress in primary cultured rat mesangial cells. Am. J. Physiol. Renal Physiol. 301, F179–F188 (2011)PubMed

125.

F. Barutta, S. Grimaldi, I. Franco, S. Bellini, R. Gambino, S. Pinach, A. Corbelli, G. Bruno, M.P. Rastaldi, T. Aveta, E. Hirsch, V. Di Marzo, G. Gruden, Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice. Kidney Int. (2014). doi:10.1038/ki.2014.165 PubMed

126.

K.A. Jenkin, A.J. McAinch, J.F. Briffa, Y. Zhang, D.J. Kelly, C.A. Pollock, P. Poronnik, D.H. Hryciw, Cannabinoid receptor 2 expression in human proximal tubule cells is regulated by albumin independent of ERK1/2 signaling. Cell. Physiol. Biochem. 32, 1309–1319 (2013)PubMed

127.

P. Janiak, B. Poirier, J.P. Bidouard, C. Cadrouvele, F. Pierre, L. Gouraud, I. Barbosa, J. Dedio, J.P. Maffrand, G. Le Fur, S. O’Connor, J.M. Herbert, Blockade of cannabinoid CB1 receptor improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int. 72, 1345–1357 (2007)PubMed

128.

F. Montecucco, F. Burger, F. Mach, S. Steffens, CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am. J. Physiol. Heart Circ. Physiol. 294, H1145–H1155 (2008)PubMed

129.

J. Tam, V.K. Vemuri, J. Liu, S. Bátkai, B. Mukhopadhyay, G. Godlewski, D. Osei-Hyiaman, S. Ohnuma, S.V. Ambudkar, J. Pickel, A. Makriyannis, G. Kunos, Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J. Clin. Invest. 120, 2953–2966 (2010)PubMedPubMedCentral

130.

S. Steffens, N.R. Veillard, C. Arnaud, G. Pelli, F. Burger, C. Staub, M. Karsak, A. Zimmer, J.L. Frossard, F. Mach, Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434, 782–786 (2005)PubMed

131.

G.D. Duerr, J.C. Heinemann, G. Suchan, E. Kolobara, D. Wenzel, C. Geisen, M. Matthey, K. Passe-Tietjen, W. Mahmud, A. Ghanem, K. Tiemann, J. Alferink, S. Burgdorf, R. Buchalla, A. Zimmer, B. Lutz, A. Welz, B.K. Fleischmann, O. Dewald, The endocannabinoid-CB2 receptor axis protects the ischemic heart at the early stage of cardiomyopathy. Basic Res. Cardiol. 109, 425 (2014)PubMed

132.

E.J. Rahn, A.G. Hohmann, Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics. 6, 713–737 (2009)PubMedPubMedCentral

133.

P. Pacher, R. Mechoulam, Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog. Lipid Res. 50, 193–211 (2011)PubMedPubMedCentral

134.

V. Deveaux, T. Cadoudal, Y. Ichigotani, F. Teixeira-Clerc, A. Louver, S. Manin, J. Tran-Van Nhieu, M.P. Belot, A. Zimmer, P. Even, P.D. Cani, C. Knauf, R. Burcelin, A. Bertola, Y. Le Marchand-Brustel, P. Gual, A. Mallat, S. Lotersztajn, Cannabinoid CB2 receptor potentiates obesity-associated inflammation, Insulin resistance and hepatic steatosis. PloS One. 4(6), e5844 (2009)

Titel: Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment
verfasst von: Federica Barutta
Graziella Bruno
Serena Grimaldi
Gabriella Gruden
Publikationsdatum: 01.04.2015
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 3/2015
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-014-0437-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

Acute effects of acylated ghrelin on salbutamol-induced metabolic actions in humans

Safety and efficacy of a multiphase dietetic protocol with meal replacements including a step with very low calorie diet

How hybrid SPECT/CT systems changed imaging work-up in detecting parathyroid adenoma (PA)

Protective effect of Schisandrae chinensis oil on pancreatic β-cells in diabetic rats

Natural course of hypogonadism diagnosed during hospitalization in aged male patients